Imunon, Inc. (IMNN) shareholders
Close on Nov 17, 2026Market cap $3.44MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 450,315 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 349,917 | 9.99% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMNN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 144,767 | 2.58% | $257.69K | −203,563 | 0.00% |
| Vanguard Capital Management LLC | 46,967 | 0.84% | $83.60K | −1,089 | 0.00% |
| Riverview Capital Advisers, LLC | 34,364 | 0.61% | $247.77K | – | 0.07% |
| Geode Capital Management, LLC | 31,629 | 0.56% | $56.30K | −1,582 | 0.00% |
| Virtu Financial LLC | 17,456 | 0.31% | $31.00K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 13,269 | 0.24% | $23.62K | – | 0.00% |
| Northern Trust Corp | 10,342 | 0.18% | $18.41K | New | 0.00% |
| UBS Group AG | 5,203 | 0.09% | $9.26K | +4,628 | 0.00% |
| BlackRock, Inc. | 4,464 | 0.08% | $7.95K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,952 | 0.07% | $7.04K | +2,086 | 0.00% |
| Wells Fargo & Company/Mn | 3,342 | 0.06% | $5.95K | – | 0.00% |
| Morgan Stanley | 1,574 | 0.03% | $2.80K | −1,461 | 0.00% |
| SBI Securities Co., Ltd. | 1,027 | 0.02% | $1.83K | – | 0.00% |
| Barclays PLC | 194 | 0.00% | $345 | New | 0.00% |
| JPMorgan Chase & Co | 134 | 0.00% | $241 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 8 | 0.00% | $14 | New | 0.00% |
| Group One Trading, L.P. | 6 | 0.00% | $11 | – | 0.00% |
| Northwestern Mutual Wealth Management Co | 3 | 0.00% | $5 | New | 0.00% |
| Osaic Holdings, Inc. | 2 | 0.00% | $3 | – | 0.00% |
| Steigerwald, Gordon & Koch Inc. | 1 | 0.00% | $2 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 0M | 5.7% | 6 / 2 | 4 / 2 | 0M | 0M |
| Q1 2026 | 19 | 1M | 9.0% | 3 / 6 | 3 / 3 | 0M | 0M |
| Q4 2025 | 20 | 0M | 7.7% | 3 / 4 | 6 / 0 | 0M | 0M |
| Q3 2025 | 17 | 0M | 2.8% | 16 / 1 | 0 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held IMNN in Q2 2026, 63% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMNN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 46,967 | 0.84% | $83.60K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 20,413 | 0.36% | $44.50K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,744 | 0.08% | $10.34K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,776 | 0.03% | $3.87K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 163 | 0.00% | $355 | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stacy Lindborg | President and CEO, Director | 123,359 | 2.20% | Nov 10, 2026 |
| Michael H. Tardugno | Executive Chairman of Board, Director | 133,133 | 2.37% | Nov 10, 2026 |
| Douglas Vincent Faller | Chief Medical Officer | 76,356 | 1.36% | Nov 10, 2026 |
| Susan Eylward | General Counsel and Corp Sec | 2,896 | 0.05% | Sep 1, 2026 |
| Joshua Blacher | CFO | – | – | Jul 7, 2026 |
| Jeffrey Wayne Church | CFO | 26 | 0.00% | Jan 20, 2026 |
| Kimberly Bragg | CFO | 20,400 | 0.36% | Jan 6, 2026 |
| Khursheed Anwer | Chief Scientific Officer | 5,000 | 0.09% | Jan 6, 2026 |
| Christine A. Pellizzari | Director | 28,665 | 0.51% | Nov 10, 2026 |
| Frederick J. Fritz | Director | 46,292 | 0.82% | Nov 10, 2026 |
| James E. Dentzer | Director | 34,197 | 0.61% | Nov 10, 2026 |
| Donald P. Braun | Director | 33,643 | 0.60% | Nov 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Donald P. Braun Director | Nov 6, 2026 | Award | +11,746 | $0.84 | $9.93K | 33,643 |
| James E. Dentzer Director | Nov 6, 2026 | Award | +13,166 | $0.84 | $11.13K | 34,197 |
| Frederick J. Fritz Director | Nov 6, 2026 | Award | +13.166 | $0.84 | $11 | 28,242 |
| Christine A. Pellizzari Director | Nov 6, 2026 | Award | +13,166 | $0.84 | $11.13K | 28,665 |
| Douglas Vincent Faller Chief Medical Officer | Nov 6, 2026 | Award | +1,596 | $0.84 | $1.35K | 76,356 |
| Stacy Lindborg President and CEO, Director | Nov 6, 2026 | Award | +3,804 | $0.84 | $3.21K | 122,581 |
| Michael H. Tardugno Executive Chairman of Board, Director | Nov 6, 2026 | Award | +9,969 | $0.84 | $8.42K | 128,511 |
| Michael H. Tardugno Executive Chairman of Board, Director | Oct 23, 2026 | Award | +6,821 | $1.24 | $8.42K | 118,542 |
| Stacy Lindborg President and CEO, Director | Oct 23, 2026 | Award | +2,603 | $1.24 | $3.21K | 118,777 |
| Douglas Vincent Faller Chief Medical Officer | Oct 23, 2026 | Award | +1,092 | $1.24 | $1.35K | 48,019 |
| Douglas Vincent Faller Chief Medical Officer | Oct 23, 2026 | Award | +26,741 | $1.24 | $33.03K | 74,760 |
| Michael H. Tardugno Executive Chairman of Board, Director | Oct 9, 2026 | Award | +7,800 | $1.08 | $8.42K | 111,721 |
| Stacy Lindborg President and CEO, Director | Oct 9, 2026 | Award | +2,977 | $1.08 | $3.22K | 116,174 |
| Douglas Vincent Faller Chief Medical Officer | Oct 9, 2026 | Award | +1,249 | $1.08 | $1.35K | 46,927 |
| Stacy Lindborg President and CEO, Director | Sep 25, 2026 | Award | +6,697 | $1.41 | $9.44K | 113,197 |
| Douglas Vincent Faller Chief Medical Officer | Sep 25, 2026 | Award | +4,390 | $1.41 | $6.19K | 45,678 |
| Michael H. Tardugno Executive Chairman of Board, Director | Sep 25, 2026 | Award | +7,169 | $1.41 | $10.11K | 103,921 |
| Stacy Lindborg President and CEO, Director | Sep 11, 2026 | Award | +5,504 | $1.47 | $8.09K | 105,580 |
| Michael H. Tardugno Executive Chairman of Board, Director | Sep 11, 2026 | Award | +5,824 | $1.47 | $8.56K | 95,699 |
| Douglas Vincent Faller Chief Medical Officer | Sep 11, 2026 | Award | +4,211 | $1.47 | $6.19K | 41,288 |
| Susan Eylward General Counsel and Corp Sec | Aug 31, 2026 | Sale | −2,525 | $1.56 | $3.94K | 2,896 |
| Susan Eylward General Counsel and Corp Sec | Aug 28, 2026 | Award | +2,525 | $1.60 | $4.04K | 5,421 |
| Michael H. Tardugno Executive Chairman of Board, Director | Aug 28, 2026 | Award | +7,371 | $1.60 | $11.79K | 89,875 |
| Stacy Lindborg President and CEO, Director | Aug 28, 2026 | Award | +6,822 | $1.60 | $10.92K | 100,076 |
| Douglas Vincent Faller Chief Medical Officer | Aug 28, 2026 | Award | +3,626 | $1.60 | $5.80K | 37,077 |
| Susan Eylward General Counsel and Corp Sec | Aug 17, 2026 | Sale | −2,449 | $1.63 | $3.99K | 2,896 |
| Michael H. Tardugno Executive Chairman of Board, Director | Aug 14, 2026 | Award | +7,147 | $1.65 | $11.79K | 82,504 |
| Susan Eylward General Counsel and Corp Sec | Aug 14, 2026 | Award | +2,449 | $1.65 | $4.04K | 5,345 |
| Stacy Lindborg President and CEO, Director | Aug 14, 2026 | Award | +6,615 | $1.65 | $10.91K | 93,254 |
| Douglas Vincent Faller Chief Medical Officer | Aug 14, 2026 | Award | +3,516 | $1.65 | $5.80K | 33,451 |
| Susan Eylward General Counsel and Corp Sec | Aug 3, 2026 | Sale | −2,541 | $1.57 | $3.99K | 2,896 |
| Christine A. Pellizzari Director | Jul 31, 2026 | Award | +6,934 | $1.59 | $11.03K | 15,076 |
| Stacy Lindborg President and CEO, Director | Jul 31, 2026 | Award | +5,010 | $1.59 | $7.97K | 86,639 |
| Donald P. Braun Director | Jul 31, 2026 | Award | +6,180 | $1.59 | $9.83K | 15,499 |
| Frederick J. Fritz Director | Jul 31, 2026 | Award | +6,934 | $1.59 | $11.03K | 21,031 |
| Susan Eylward General Counsel and Corp Sec | Jul 31, 2026 | Award | +2,541 | $1.59 | $4.04K | 5,437 |
| James E. Dentzer Director | Jul 31, 2026 | Award | +6,934 | $1.59 | $11.03K | 21,897 |
| Douglas Vincent Faller Chief Medical Officer | Jul 31, 2026 | Award | +3,649 | $1.59 | $5.80K | 29,935 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jul 31, 2026 | Award | +6,358 | $1.59 | $10.11K | 75,357 |
| Susan Eylward General Counsel and Corp Sec | Jul 20, 2026 | Sale | −2,150 | $1.78 | $3.83K | 2,896 |
| Stacy Lindborg President and CEO, Director | Jul 17, 2026 | Award | +4,907 | $1.83 | $8.98K | 81,629 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jul 17, 2026 | Award | +4,603 | $1.83 | $8.42K | 68,999 |
| Douglas Vincent Faller Chief Medical Officer | Jul 17, 2026 | Award | +3,082 | $1.83 | $5.64K | 26,286 |
| Susan Eylward General Counsel and Corp Sec | Jul 17, 2026 | Award | +2,150 | $1.83 | $3.93K | 5,046 |
| Susan Eylward General Counsel and Corp Sec | Jul 6, 2026 | Sale | −920 | $1.88 | $1.73K | 2,896 |
| Susan Eylward General Counsel and Corp Sec | Jul 2, 2026 | Award | +920 | $1.91 | $1.76K | 3,816 |
| Stacy Lindborg President and CEO, Director | Jul 2, 2026 | Award | +2,534 | $1.91 | $4.84K | 76,722 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jul 2, 2026 | Award | +4,410 | $1.91 | $8.42K | 64,396 |
| Douglas Vincent Faller Chief Medical Officer | Jul 2, 2026 | Award | +1,308 | $1.91 | $2.50K | 23,204 |
| Susan Eylward General Counsel and Corp Sec | Jun 29, 2026 | Sale | −11,800 | $1.75 | $20.65K | 2,896 |
| Douglas Vincent Faller Chief Medical Officer | Jun 25, 2026 | Award | +21,896 | $1.72 | $37.66K | 21,896 |
| Stacy Lindborg President and CEO, Director | Jun 25, 2026 | Award | +67,150 | $1.72 | $115.50K | 74,188 |
| Susan Eylward General Counsel and Corp Sec | Jun 25, 2026 | Award | +14,696 | $1.72 | $25.28K | 14,696 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jun 25, 2026 | Award | +42,519 | $1.72 | $73.13K | 59,986 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jun 18, 2026 | Award | +4,629 | $1.82 | $8.42K | 17,467 |
| Stacy Lindborg President and CEO, Director | Jun 18, 2026 | Award | +1,803 | $1.82 | $3.28K | 7,038 |
| Michael H. Tardugno Executive Chairman of Board, Director | Jun 5, 2026 | Award | +4,089 | $2.06 | $8.42K | 12,838 |
| Stacy Lindborg President and CEO, Director | Jun 5, 2026 | Award | +1,593 | $2.06 | $3.28K | 5,235 |
| Frederick J. Fritz Director | May 22, 2026 | Award | +10,330 | $2.20 | $22.73K | 14,097 |
| Donald P. Braun Director | May 22, 2026 | Award | +5,011 | $2.20 | $11.02K | 9,319 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Imunon's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,937 shares on Aug 20, 2026 over the last 90 days.
Congress trades
4 trades in Imunon reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Roger W. Marshall KS01 · child | Sold | Jun 16, 2017 | $1K–15K | Aug 6, 2018 416 days late |
| Roger W. Marshall KS01 · child | Bought | Jun 16, 2017 | $1K–15K | Aug 6, 2018 416 days late |
| Roger W. Marshall KS01 · child | Sold | Jun 5, 2017 | $1K–15K | Aug 6, 2018 427 days late |
| Roger W. Marshall KS01 · child | Bought | Jun 5, 2017 | $1K–15K | Aug 6, 2018 427 days late |
See a number that looks wrong?